Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Jan;45(1):27–34. doi: 10.1038/bjc.1982.4

Response of a high-glucuronidase human tumour xenograft to aniline mustard.

H M Warenius, P Workman, N M Bleehen
PMCID: PMC2010942  PMID: 7059462

Abstract

The HT29R colonic adenocarcinoma xenograft has been shown to be rich in the enzyme beta-glucuronidase. Experiments in rodent systems have demonstrated a marked anti-tumour effect of the drug aniline mustard (AM) on tumours with high levels of this enzyme (e.g. the plasmacytomas PC5 and PC6). We have found that AM is no more effective than its analogue paramethyl aniline mustard (PMAM) or other alkylating agents against the HT29R xenograft. Amongst the possible explanations for this may be: (1) The wide shoulder on the cell-survival curve shown for exposure to alkylating agents of HT29R in vivo. (2) Lack of correlation between physiological availability of beta-glucuronidase and the high levels measured by the standard assay. (3) Increased beta-glucuronidase levels in host mouse marrow, making the latter potentially more susceptible to AM damage.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carl P. L., Chakravarty P. K., Katzenellenbogen J. A., Weber M. J. Protease-activated "prodrugs" for cancer chemotherapy. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2224–2228. doi: 10.1073/pnas.77.4.2224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Connors T. A., Farmer P. B., Foster A. B., Gilsenan A. M., Jarman M., Tisdale M. J. Metabolism of aniline mustard (N,N-di-(2-chloroethyl)aniline). Biochem Pharmacol. 1973 Aug 15;22(16):1971–1980. doi: 10.1016/0006-2952(73)90079-8. [DOI] [PubMed] [Google Scholar]
  3. Connors T. A., Whisson M. E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature. 1966 May 21;210(5038):866–867. doi: 10.1038/210866b0. [DOI] [PubMed] [Google Scholar]
  4. Double J. A., Workman P. A new high-glucuronidase mouse tumor curable by aniline mustard therapy. Cancer Treat Rep. 1977 Aug;61(5):909–911. [PubMed] [Google Scholar]
  5. HARPER N. J. Drug latentiation. J Med Pharm Chem. 1959 Oct;1:467–500. doi: 10.1021/jm50006a005. [DOI] [PubMed] [Google Scholar]
  6. Healy J. B. The disease, myelomatosis. Ir J Med Sci. 1968 May;7(5):211–226. doi: 10.1007/BF02958759. [DOI] [PubMed] [Google Scholar]
  7. Kopper L., Steel G. G. The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res. 1975 Oct;35(10):2704–2713. [PubMed] [Google Scholar]
  8. Kyle R. A., Costa G., Cooper M. R., Ogawa M., Silver R. T., Glidewell O., Holland J. F. Evaluation of aniline mustard in patients with multiple myeloma. Cancer Res. 1973 May;33(5):956–960. [PubMed] [Google Scholar]
  9. WHISSON M. E., CONNORS T. A. DRUG-INDUCED REGRESSION OF LARGE PLASMA CELL TUMOURS. Nature. 1965 Jan 23;205:406–406. doi: 10.1038/205406a0. [DOI] [PubMed] [Google Scholar]
  10. Warenius H. M., Freedman L. S., Bleehen N. M. The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments. Br J Cancer Suppl. 1980 Apr;4:128–132. [PMC free article] [PubMed] [Google Scholar]
  11. Whisson M. E., Connors T. A. Cure of mice bearing advanced plasma cell tumours with aniline mustard. Nature. 1965 May 15;206(985):689–691. doi: 10.1038/206689a0. [DOI] [PubMed] [Google Scholar]
  12. Workman P., Ball C. R., Double J. A. Enzyme activated anti-tumour agents- II. The role of alkaline phosphatase in the release of p-hydroxyaniline mustard from its phosphate conjugate in cells in culture. Biochem Pharmacol. 1976 May 15;25(10):1139–1144. doi: 10.1016/0006-2952(76)90360-9. [DOI] [PubMed] [Google Scholar]
  13. Workman P., Double J. A. Drug latentiation in cancer chemotherapy. Biomedicine. 1978 Oct;28(5):255–262. [PubMed] [Google Scholar]
  14. Young C. W., Yagoda A., Bittar E. S., Smith S. W., Grabstald H., Whitmore W. Therapeutic trial of aniline mustard in patients with advanced cancer. Comparison of therapeutic response with cytochemical assessment of tumor cell beta-glucuronidase activity. Cancer. 1976 Nov;38(5):1887–1895. doi: 10.1002/1097-0142(197611)38:5<1887::aid-cncr2820380504>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  15. von Kleist S., Chany E., Burtin P., King M., Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975 Sep;55(3):555–560. doi: 10.1093/jnci/55.3.555. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES